Ceritinib
ALK Fusion Protein Expression
University of California, San FranciscoSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the ALK Fusion Protein Expression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ensartinib Sichuan University | Phase 2 | CCC |
Brigatinib Sameek Roychowdhury | Phase 2 | CCC |
Regorafenib University of California, San Francisco | Phase 2 | CCC |
Entrectinib University of California, San Francisco | Phase 2 | CCC |
Capmatinib University of California, San Francisco | Phase 2 | CCC |
egf816 University of California, San Francisco | Phase 2 | CC |
Same molecule, other indications
Ceritinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →